Alzheimer'S Disease Clinical Trials in Columbia, SC

Alzheimer'S Disease Clinical Trials in Columbia, SC

View the best 10 alzheimer's disease medical studies in Columbia, South Carolina. Access promising new therapies by applying to a Columbia-based Alzheimer'S Disease clinical trial.

Trials in Columbia, South Carolina

Here are the top 10 medical studies for alzheimer's disease in Columbia, South Carolina

Image of Barrow Neurological Institute in Phoenix, United States.

Sensory Stimulation System (GS120)

Behavioural Intervention

Recruiting1 award
This trial is an extension of a previous study where participants will receive treatment with an Active Sensory Stimulation System for up to 12 months. There will be no sham treatment or randomization in this
Image of Valley Clinical Trials, Inc. in Covina, United States.

Donanemab

Monoclonal Antibodies

Verified
Recruiting1 awardPhase 3
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Image of Brain Matters Research in Delray Beach, United States.

Sensory Stimulation System (GS120) - Active +1 More

Behavioural Intervention

Verified
Recruiting0 awards1 criteria
This trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.
Image of Clinical Research Site in Toms River, United States.

AXS-05 +1 More

NMDA receptor antagonist

Verified
Recruiting1 awardPhase 3
This trial is testing a new medication called AXS-05 to see if it can help reduce agitation in people with Alzheimer's disease. The goal is to find out if AXS-05 can balance brain chemicals to calm agitation and improve behavior. AXS-05, a combination of dextromethorphan and bupropion, is being investigated for its potential to treat agitation in Alzheimer's disease and has shown promise in early clinical trials.
Image of Center for Cognitive Health in Portland, United States.

ATH-1017

Recruiting1 awardPhase 2 & 3
This trial is testing the safety and tolerability of fosgonimeton in Alzheimer's patients who have completed other studies.
Image of Barrow Neurological Institute /ID# 240388 in Phoenix, United States.

ABBV-916

Verified
Recruiting0 awardsPhase 2
This trial is testing a new drug called ABBV-916 to see if it can help people aged 50-90 who are in the early stages of Alzheimer's disease. Participants will receive the drug regularly over several months. The study aims to find out if the drug is safe and effective by monitoring changes in symptoms and side effects.
Image of Rhode Island Mood & Memory Research Institute in East Providence, United States.

Simufilam

Small Molecule

Recruiting2 awardsPhase 3
This trial looks at how safe a drug is over time for people who have already taken it in a previous trial.
Image of Facility #1 in Birmingham, United States.

Lecanemab +1 More

Monoclonal Antibodies

Recruiting0 awardsPhase 2
This trial is testing a new drug, lecanemab, to see if it's effective in treating Alzheimer's disease. The trial will last 18 months and have interim analyses to update treatment allocation. Those who complete the trial or discontinue early will be eligible for the Extension Phase, which will last up to 60 months.
Image of ATP Clinical Research, Inc. in Costa Mesa, United States.

Masupirdine

Behavioural Intervention

Recruiting1 awardPhase 3
This trial will test a medication called masupirdine, which participants will take regularly. It targets people with Alzheimer's disease who are experiencing agitation. The study aims to see if masupirdine can help reduce agitation and ensure it is safe and well-tolerated. Masupirdine has been previously evaluated in patients with moderate Alzheimer's disease and was found to be generally safe and well-tolerated.
Image of Pivotal Research Centers in Peoria, United States.

3APS

Recruiting2 awardsPhase 3
This trial is testing whether a new drug can improve symptoms in people with Alzheimer's disease.

Phase 3 Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.